These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2876513)

  • 1. The natural history of peptic ulcer disease: the influence of H2-antagonist treatment.
    Bianchi Porro G; Petrillo M
    Scand J Gastroenterol Suppl; 1986; 121():46-52. PubMed ID: 2876513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 3. H2-blockers: how safe and how effective?
    Spiro HM
    J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of H2-receptor antagonist in the treatment of peptic ulcer disease in children.
    Tam PK; Saing H
    J Pediatr Gastroenterol Nutr; 1989 Jan; 8(1):41-6. PubMed ID: 2567346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.
    Jensen DM
    Am J Med; 1986 Oct; 81(4B):42-8. PubMed ID: 2877574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histamine H2-receptor antagonists as new anti-ulcer agents].
    Takemoto T
    Nihon Rinsho; 1984 Jan; 42(1):103-13. PubMed ID: 6143835
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs.
    Di Mario F; Gottardello L; Germanà B; Dotto P; Grassi SA; Vianello F; Battaglia G; Leandro G; Burra P; Salvagnini M
    Ital J Gastroenterol; 1992; 24(3):122-5. PubMed ID: 1348650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The other option in peptic ulcer therapy.
    Halter F
    S Afr Med J; 1984 Jun; 65(25):996-1000. PubMed ID: 6374932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of surgery in the therapy of peptic ulcer after arrival of H2-blocking drugs].
    Perri S; Amendolara M; Breda E; Todarello V; Gallo G; Pietrangeli F; Meneghini G; Gelmi GF
    G Chir; 1990 Sep; 11(9):466-70. PubMed ID: 1981139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials.
    Dobrilla G; Vallaperta P; Amplatz S
    Gut; 1988 Feb; 29(2):181-7. PubMed ID: 2894337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of peptic ulcer with histamine H2 receptor antagonists].
    Domschke W; Domschke S; Demling L
    Fortschr Med; 1977 Aug; 95(31):1899-902. PubMed ID: 19347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine H2-receptor antagonist in treatment of peptic ulcer.
    Wyllie JH
    Postgrad Med; 1978 Apr; 63(4):91-6, 100. PubMed ID: 345252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peptic ulcer: new aspects of conservative therapy].
    Bernoulli R
    Schweiz Med Wochenschr; 1977 May; 107(18):618-22. PubMed ID: 17157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Currents aspects of H2 receptor antagonists in the treatment of ulcers].
    Debongnie JC
    Acta Gastroenterol Belg; 1992; 55(5-6):415-22. PubMed ID: 1363166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical, secretory, radiological and endoscopic evolution of patients with gastroduodenal ulcer treated with Ulcosilvanil, as compared with those treated with histamine H2 receptor antagonists].
    Contraşiu P; Calinici V
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1980; 32(4):359-63. PubMed ID: 6113650
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of H2 blockers on the surgical indications for peptic ulcer].
    da Silva JG; Zeitune JM; Bettarello A
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):189-92. PubMed ID: 2576895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists.
    Bardhan KD; Nayyar AK; Royston C
    Dig Liver Dis; 2003 Aug; 35(8):529-36. PubMed ID: 14567455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
    Simon B; Müller P; Dammann HG
    Wien Med Wochenschr; 1982 May; 132(10):223-8. PubMed ID: 6126962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.